Marketing that scientists don't roll their eyes at, for biotech and TechBio companies selling platforms and pipelines to pharma R&D.
Senior-led, every claim reviewed by your scientists, 30-day cancellation notice. Your first call is with a co-founder.
Building credibility is now a top priority for 67% of scientific-audience companies, up from 22% in 2021 (AZoNetwork). Scientists check the literature before they take a call.
The most common marketing department in scientific companies runs two to five people (AZoNetwork, 2025); many platform biotechs run none, and the CEO reviews every slide.
Platform sales into pharma take six to 18 months and often start as paid pilots (Compound VC). Research institutes decide faster, at far smaller deal sizes.
Roughly 50 pharma companies matter globally, and 30+ TechBio contracts were signed in all of 2025 (Health Tech Report). Every buyer talks to every other buyer.
Lab instruments, tools and CRO services are adjacent but different work. This page, and this team, are for platform and therapeutics companies.
Drafts reach your scientists at outline stage, so review shapes a piece instead of killing it. Published papers, preprints and posters become readable assets for BD and investors, and nothing goes out without a technical sign-off.
The buyer list is finite: therapeutic-area teams, computational groups and BD&L contacts at the majors, plus the mid-pharma tier that moves faster. Campaigns run against that named list and report accounts engaged, not clicks bought.
BIO logged 66,308 partnering meetings in 2025, and the calendar from JPM to BIO-Europe is where biotech deals start. We treat each conference as a campaign: a target meeting list, pre-booked outreach, follow-up nurture.
One narrative serves the raise and the partnering conversation, because pharma validation moves your round and a strong round steadies pharma's confidence. The story is written once, then cut in registers for scientists, BD teams and investors.
Scientists follow people, not company pages. We build the founder's channel on their actual thinking: drafted to an outline, written in their voice, approved by them, with engaged accounts flagged to sales every week.
Nothing ships that your scientists wouldn't put their name under.
We work pay-as-you-go on hourly rates, with a 30-day cancellation notice. Biotech engagements usually start narrow, one audience and one channel pair, then widen as the data earns it.
Every figure in this section sits on a published case study, Cradle's or Coforix's, with the method on the page.
We don’t work from a template. Your Head of Growth builds the plan around your science, your pharma buyers and the partnering calendar you sell into. The cards below show one example for a TechBio company.
Platforms, AI-for-biology and therapeutics developers selling to pharma R&D, scientists and investors. Evidence bar: peer-reviewed credibility. Client: Cradle.
Software and AI sold to hospitals and health systems through committee buying. Buyer: CIOs, CMIOs, clinical operations. Client: Coforix. Covered on the hub.
The parent page maps all five segments, from medtech to diagnostics, with the buyer, regulation and sales motion for each.
The report's TechBio chapter covers who signs platform deals, where budget sits inside pharma, and why digital health teams don't hold the money.
Amsterdam and New York, covering EU biotech hubs and the US coasts. Cradle runs from Amsterdam and Zurich.